Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to Sell at StockNews.comZolmax • 22 days ago
StockNews.com cut shares of Aclaris Therapeutics (NASDAQ:ACRS - Free Report) from a hold rating to a sell rating in a research note released on Tuesday morning.
Several other brokerages also recently...
Share to Feed
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling...
StockNews.com upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS Free Report) from a sell rating to a hold rating in a research report released on Monday morning.
Other equities research...
Biotech's Role in Addressing the Pancreatic Cancer Emergency Biotech's Role in Addressing the Pancreatic Cancer Emergency PR Newswire VANCOUVER, BC, March 14, 2024 FN Media Group Presents USA News...
Investors considering a purchase of Aclaris Therapeutics Inc (ACRS) stock, but tentative about paying the going market price of 1.29/share, might benefit from considering selling puts among the...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Connect Biopharma Holdings (CNTB Research Report), Aethlon Medical...
H.C. Wainwright analyst Ram Selvaraju has reiterated their neutral stance on ACRS stock, giving a Hold rating on February 27. Ram Selvaraju has giv...
Algert Global LLC purchased a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS Free Report) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 45,120 shares of the...
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics, Inc. (NASDAQ:ACRS Get Free Report) has been given an average recommendation of Hold by the eight research firms that are currently covering the company...